Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

PubMed Links for Books (Select 2356396)

1.

Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study.

Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, Phillips A, Pillay D, Porter K, Pozniak A, Sabin C, Smit E, Weber J, Zuckerman M; UK Group on Transmitted HIV Drug Resistance.

BMJ. 2005 Dec 10;331(7529):1368. Epub 2005 Nov 18.

2.

Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.

Wirden M, Malet I, Derache A, Marcelin AG, Roquebert B, Simon A, Kirstetter M, Joubert LM, Katlama C, Calvez V.

AIDS. 2005 Mar 24;19(6):630-2.

PMID:
15802984
3.

Non-disclosure of previously known HIV seropositivity in patients "newly" diagnosed with HIV infection.

Natha M, Newell A, Pakianathan M.

Sex Transm Infect. 2005 Apr;81(2):182-3. No abstract available.

4.

Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients.

Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, Kolber MA.

AIDS. 2005 Mar 4;19(4):447-9. No abstract available.

PMID:
15750401
5.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Jan 28;19(2):153-62. No abstract available. Corrected and republished in: AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15668540
6.

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study.

Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J.

HIV Med. 2004 Sep;5(5):344-51.

PMID:
15369509
7.

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen.

Friend J, Parkin N, Liegler T, Martin JN, Deeks SG.

AIDS. 2004 Sep 24;18(14):1965-6. No abstract available.

PMID:
15353986
8.

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.

JAMA. 2004 Jul 14;292(2):191-201.

PMID:
15249568
9.

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W.

AIDS. 2004 Mar 5;18(4):651-5.

PMID:
15090770
10.

Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, D'Elia S, Chiodo F, Ghinelli F, Bertoli A, d'Arminio Monforte A, Perno CF, Moroni M, Balotta C.

AIDS. 2004 Jan 23;18(2):227-35.

PMID:
15075540
11.

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, Wulfsohn M.

J Infect Dis. 2004 Mar 1;189(5):837-46. Epub 2004 Feb 10.

12.

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun E.

J Infect Dis. 2004 Jan 1;189(1):51-60. Epub 2003 Dec 31.

13.

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.

Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

J Infect Dis. 2003 Aug 15;188(4):537-40. Epub 2003 Jul 24.

14.

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

García-Lerma JG, MacInnes H, Bennett D, Reid P, Nidtha S, Weinstock H, Kaplan JE, Heneine W.

J Virol. 2003 May;77(10):5685-93.

15.

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.

Antivir Ther. 2002 Sep;7(3):165-74.

PMID:
12487383
16.
17.

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team.

AIDS. 2002 Aug 16;16(12):1686-9.

PMID:
12172093
19.

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T.

Hepatology. 1999 Nov;30(5):1302-6.

PMID:
10534354
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk